Do patients with Lynch syndrome require routine esophagogastroduodenoscopy (EGD) for upper gastrointestinal cancer surveillance?

EGD Surveillance in Lynch Syndrome: Not Routinely Required for All Patients

Routine EGD surveillance is not universally recommended for all patients with Lynch syndrome, but should be strongly considered for selected high-risk individuals, particularly those with MLH1, MSH2, or EPCAM mutations, those of Asian descent, or those with a family history of upper gastrointestinal cancers. 1

Evidence-Based Approach to Upper GI Surveillance

General Population with Lynch Syndrome

The major guidelines consistently state that there is no clear evidence to support routine screening for gastric, duodenal, and small bowel cancer in all patients with Lynch syndrome 1. This reflects the relatively modest absolute risk in unselected populations and the lack of proven mortality benefit from universal screening.

High-Risk Subgroups Warranting EGD Surveillance

EGD with extended duodenoscopy should be considered every 3-5 years starting at age 30-35 years for: 1

• Selected individuals or families with significant upper GI cancer history
• Patients of Asian descent (due to substantially higher gastric cancer rates, up to 30% lifetime risk in Korean populations versus 2-4% in Western populations) 1
• Carriers of MLH1, MSH2, or EPCAM mutations (highest risk group)

The most recent 2024 NCCN guidelines have evolved to recommend upper GI surveillance with high-quality EGD starting at age 30-40 years and repeated every 2-4 years, preferably performed in conjunction with colonoscopy 1. This represents a shift toward broader surveillance compared to earlier guidelines.

Gene-Specific Risk Stratification

MSH2 and MLH1 carriers face the highest upper GI cancer risk 2, 3:

• Cumulative incidence of gastric cancer by age 70-75: 3-5% for high-risk pathogenic variants (MLH1/MSH2/EPCAM) versus 1% for low-risk variants (MSH6/PMS2) 2
• Cumulative incidence of duodenal cancer by age 70-75: 5-6% for high-risk variants versus 1-2% for low-risk variants 2
• Risk remains very low (<1%) before age 50 for all gene types 2

MSH6 and PMS2 carriers have substantially lower upper GI cancer risk, though limited data prevent definitive gene-specific screening recommendations 1.

Yield of EGD Surveillance

Recent research demonstrates meaningful detection rates that support selective surveillance:

• Clinically actionable findings detected in 17.6% of asymptomatic Lynch syndrome patients undergoing EGD surveillance 4
• Upper GI cancers detected in 0.9% of screening EGDs (pooled event rate from meta-analysis) 5
• High-risk lesions detected in 4.2% of EGDs 5
• Early-stage cancer detection in 1.5% of patients, with all cancers detected at early, treatable stages 4
• Neoplastic upper GI lesions found in 26% of Lynch syndrome patients, particularly those over age 40 6

Importantly, 71% of duodenal cancers were detected at early stage in the surveillance group versus only 29% in the non-surveillance group (p=0.021), demonstrating clear benefit of surveillance for early detection 7.

Essential Helicobacter pylori Management

All Lynch syndrome patients should be tested for H. pylori and treated if positive, regardless of whether they undergo EGD surveillance 1. This recommendation is consistent across NCCN, ASCO, and ESMO guidelines.

• H. pylori infection is associated with 5.5-fold increased risk of gastric cancer in Lynch syndrome 3
• H. pylori infection significantly increases prevalence of gastric (but not duodenal) lesions 6
• One-time noninvasive testing should be performed at Lynch syndrome diagnosis for those not undergoing endoscopic surveillance 1

Practical Implementation

For patients undergoing EGD surveillance: 1

• Perform high-quality EGD with both forward and side-viewing scopes
• Extend examination to distal duodenum or into jejunum 1
• Random biopsy of proximal and distal stomach on initial procedure to assess for H. pylori, autoimmune gastritis, and intestinal metaplasia 1
• Consider push enteroscopy to enhance small bowel visualization, though incremental yield remains uncertain 1
• Coordinate timing with colonoscopy when feasible 1

Age of initiation may be earlier than 30 years (as early as 25 years) based on family history of upper GI cancers or high-risk endoscopic findings such as incomplete or extensive gastric intestinal metaplasia, gastric or duodenal adenomas, or Barrett's esophagus with dysplasia 1, 7.

Surveillance intervals may be shortened to <2 years based on family history or high-risk findings 1.

Common Pitfalls to Avoid

• Do not assume all Lynch syndrome patients require EGD: Risk stratification by gene, ethnicity, and family history is essential 1
• Do not neglect H. pylori testing: This simple intervention may reduce gastric cancer risk and should be universal 1
• Do not perform inadequate examination: Extended duodenoscopy into the jejunum is necessary, as approximately 50% of small bowel cancers in Lynch syndrome are duodenal and accessible by EGD 7
• Do not ignore family history: Personal and family history of upper GI cancers should lower the threshold for surveillance and may warrant earlier initiation 1, 7